{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:55:13Z","timestamp":1783508113310,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014164","name":"ProQR Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81-XWH\u201009\u20102\u20100189"],"award-info":[{"award-number":["W81-XWH\u201009\u20102\u20100189"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81\u2010XWH\u201007\u20101\u20100720"],"award-info":[{"award-number":["W81\u2010XWH\u201007\u20101\u20100720"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["201711107A"],"award-info":[{"award-number":["201711107A"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18ek0109355h0001"],"award-info":[{"award-number":["18ek0109355h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007253","name":"Bedford Institute of Oceanography","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012617","name":"Moorfields Eye Hospital NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013368","name":"Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften","doi-asserted-by":"publisher","award":["LPDS 2015-14"],"award-info":[{"award-number":["LPDS 2015-14"]}],"id":[{"id":"10.13039\/501100013368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16H06269"],"award-info":[{"award-number":["16H06269"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16KK01930002"],"award-info":[{"award-number":["16KK01930002"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018030","name":"NightstaRx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000625","name":"Great Britain Sasakawa Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["J 3383-B23"],"award-info":[{"award-number":["J 3383-B23"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002806","name":"Carl Zeiss Meditec AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY009076"],"award-info":[{"award-number":["EY009076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ajo.2021.04.015","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T17:15:39Z","timestamp":1619975739000},"page":"123-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The Progression of Stargardt Disease Using Volumetric Hill of Vision Analyses Over 24 Months: ProgStar Report No.15"],"prefix":"10.1016","volume":"230","author":[{"given":"Etienne M.","family":"Sch\u00f6nbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Janeschitz-Kriegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert W.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-8431","authenticated-orcid":false,"given":"Marco E.G.V.","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4248-0033","authenticated-orcid":false,"given":"Kaoru","family":"Fujinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-0905","authenticated-orcid":false,"given":"Artur V.","family":"Cideciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-0780","authenticated-orcid":false,"given":"Janet S.","family":"Sunness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Weleber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik P.N.","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2021.04.015_bib0001","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1073\/pnas.1913179117","article-title":"Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases","volume":"117","author":"Hanany","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"368","key":"10.1016\/j.ajo.2021.04.015_bib0002","doi-asserted-by":"crossref","first-page":"368rv366","DOI":"10.1126\/scitranslmed.aaf2838","article-title":"Emerging therapies for inherited retinal degeneration","volume":"8","author":"Scholl","year":"2016","journal-title":"Sci Transl Med"},{"issue":"7705","key":"10.1016\/j.ajo.2021.04.015_bib0003","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-018-0076-4","article-title":"Restoring vision","volume":"557","author":"Roska","year":"2018","journal-title":"Nature"},{"issue":"9967","key":"10.1016\/j.ajo.2021.04.015_bib0004","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","article-title":"Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1\/2 studies","volume":"385","author":"Schwartz","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ajo.2021.04.015_bib0005","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.ophtha.2018.04.037","article-title":"Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration","volume":"125","author":"Mehat","year":"2018","journal-title":"Ophthalmology"},{"issue":"9923","key":"10.1016\/j.ajo.2021.04.015_bib0006","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(14)60033-7","article-title":"Gene therapy arrives at the macula","volume":"383","author":"Scholl","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ajo.2021.04.015_bib0007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/tvst.5.5.10","article-title":"Test-retest variability of functional and structural parameters in patients with Stargardt disease participating in the SAR422459 gene therapy trial","volume":"5","author":"Parker","year":"2016","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2021.04.015_bib0008","article-title":"Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives","author":"Garafalo","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"10.1016\/j.ajo.2021.04.015_bib0009","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.ophtha.2018.03.059","article-title":"Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: A randomized clinical trial","volume":"125","author":"Rosenfeld","year":"2018","journal-title":"Ophthalmology"},{"issue":"27","key":"10.1016\/j.ajo.2021.04.015_bib0010","doi-asserted-by":"crossref","first-page":"8415","DOI":"10.1073\/pnas.1506960112","article-title":"Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization","volume":"112","author":"Charbel Issa","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ajo.2021.04.015_bib0011","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ophtha.2015.12.009","article-title":"The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies: Design and baseline characteristics: ProgStar Report No. 1","volume":"123","author":"Strauss","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2021.04.015_bib0012","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamaophthalmol.2020.1735","article-title":"Longitudinal microperimetric changes of macular sensitivity in Stargardt disease after 12 months: ProgStar Report No. 13","volume":"138","author":"Sch\u00f6nbach","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2021.04.015_bib0013","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamaophthalmol.2017.1162","article-title":"Macular sensitivity measured with microperimetry in Stargardt disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7","volume":"135","author":"Sch\u00f6nbach","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.015_bib0014","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.4.2.14","article-title":"VFMA: Topographic analysis of sensitivity data from full-field static perimetry","volume":"4","author":"Weleber","year":"2015","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"10.1016\/j.ajo.2021.04.015_bib0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bjophthalmol-2018-312064","article-title":"Detailed genetic characteristics of an international large cohort of patients with Stargardt disease: ProgStar study report 8","volume":"103","author":"Fujinami","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2021.04.015_bib0016","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/humu.23165","article-title":"In silico functional meta-analysis of 5,962 ABCA4 variants in 3,928 retinal dystrophy cases","volume":"38","author":"Cornelis","year":"2017","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.ajo.2021.04.015_bib0017","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1167\/iovs.17-23364","article-title":"Correlating the expression and functional activity of ABCA4 disease variants with the phenotype of patients with Stargardt disease","volume":"59","author":"Garces","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2021.04.015_bib0018","first-page":"546","article-title":"Variants in the ABCA4 gene in a Brazilian population with Stargardt disease","volume":"24","author":"Salles","year":"2018","journal-title":"Mol Vis"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.015_bib0019","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1167\/iovs.16-19936","article-title":"Mutation spectrum of the ABCA4 gene in 335 Stargardt disease patients from a multicenter German cohort-impact of selected deep intronic variants and common SNPs","volume":"58","author":"Schulz","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2021.04.015_bib0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jamaophthalmol.2017.1121","article-title":"Incidence of atrophic lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study: Report no. 5","volume":"135","author":"Strauss","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2021.04.015_bib0021","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.oret.2017.02.008","article-title":"Progression of visual acuity and fundus autofluorescence in recent onset Stargardt disease: ProgStar study report #4","volume":"1","author":"Kong","year":"2017","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"10.1016\/j.ajo.2021.04.015_bib0022","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaophthalmol.2017.4152","article-title":"Progression of Stargardt disease as determined by fundus autofluorescence in the retrospective Progression of Stargardt Disease study (ProgStar Report No. 9)","volume":"135","author":"Strauss","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.015_bib0023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1167\/tvst.8.2.16","article-title":"A workshop on measuring the progression of atrophy secondary to Stargardt disease in the ProgStar studies: Findings and lessons learned","volume":"8","author":"Ervin","year":"2019","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"10.1016\/j.ajo.2021.04.015_bib0024","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2021.04.015_bib0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group","volume":"81","year":"1976","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2021.04.015_bib0026","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jamaophthalmol.2018.2198","article-title":"Visual acuity change over 24 months and its association with foveal phenotype and genotype in individuals with Stargardt disease: ProgStar Study Report No. 10","volume":"136","author":"Kong","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2021.04.015_bib0027","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.ophtha.2017.04.026","article-title":"Visual acuity change over 12 months in the prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study: ProgStar Report Number 6","volume":"124","author":"Kong","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2021.04.015_bib0028","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ophtha.2016.05.027","article-title":"Visual acuity loss and associated risk factors in the retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2)","volume":"123","author":"Kong","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2021.04.015_bib0029","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/IAE.0b013e31816690bd","article-title":"Retinal function and loss of autofluorescence in Stargardt Disease","volume":"28","author":"Sunness","year":"2008","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2021.04.015_bib0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/ICB.0b013e31806011e6","article-title":"What you see is not always what you get in atrophic macular disease","volume":"2","author":"Sunness","year":"2008","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.015_bib0031","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.oret.2016.08.009","article-title":"Fixation location and stability using the MP-1 microperimeter in Stargardt disease: ProgStar Report No. 3","volume":"1","author":"Sch\u00f6nbach","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2021.04.015_bib0032","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ajo.2018.06.003","article-title":"Longitudinal changes of fixation location and stability within 12 months in Stargardt disease: ProgStar Report No. 12","volume":"193","author":"Sch\u00f6nbach","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2021.04.015_bib0033","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/jamaophthalmol.2019.2885","article-title":"Progression of Stargardt disease as determined by fundus autofluorescence over a 12-month period: ProgStar Report No. 11","volume":"137","author":"Strauss","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.015_bib0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bjophthalmol-2016-308823","article-title":"Stargardt disease: Clinical features, molecular genetics, animal models and therapeutic options","volume":"101","author":"Tanna","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2021.04.015_bib0035","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.ophtha.2014.06.032","article-title":"Macular function and morphologic features in juvenile Stargardt disease: Longitudinal study","volume":"121","author":"Testa","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2021.04.015_bib0036","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/IAE.0000000000001003","article-title":"Mapping the dense scotoma and its enlargement in Stargardt disease","volume":"36","author":"Bernstein","year":"2016","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.015_bib0037","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00417-016-3466-z","article-title":"Long-term longitudinal modifications in mesopic microperimetry in early and intermediate age-related macular degeneration","volume":"255","author":"Vujosevic","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2021.04.015_bib0038","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1364\/JOSAA.24.001457","article-title":"Reduced-illuminance autofluorescence imaging in ABCA4-associated retinal degenerations","volume":"24","author":"Cideciyan","year":"2007","journal-title":"J Opt Soc Am A Opt Image Sci Vis"},{"issue":"13","key":"10.1016\/j.ajo.2021.04.015_bib0039","doi-asserted-by":"crossref","first-page":"8181","DOI":"10.1167\/iovs.13-12104","article-title":"A longitudinal study of Stargardt disease: Quantitative assessment of fundus autofluorescence, progression, and genotype correlations","volume":"54","author":"Fujinami","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.015_bib0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ophtha.2014.08.012","article-title":"Clinical and molecular characteristics of childhood-onset Stargardt disease","volume":"122","author":"Fujinami","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2021.04.015_bib0041","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ajo.2013.05.003","article-title":"Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function","volume":"156","author":"Fujinami","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2021.04.015_bib0042","first-page":"3385","article-title":"One year results of a phase I\/IIa study of SAR422459 in patients with Stargardt macular degeneration (SMD)","volume":"58","author":"Wilson","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.015_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148022","article-title":"Structure-function modeling of optical coherence tomography and standard automated perimetry in the retina of patients with autosomal dominant retinitis pigmentosa","volume":"11","author":"Smith","year":"2016","journal-title":"PloS One"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:44:23Z","timestamp":1762080263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939421002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":43,"alternative-id":["S0002939421002142"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2021.04.015","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Progression of Stargardt Disease Using Volumetric Hill of Vision Analyses Over 24 Months: ProgStar Report No.15","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2021.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}